Friday - April 3, 2026
Imfinzi Plus Imjudo Combined With Lenvatinib and TACE Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Embolization-Eligible Unresectable Liver Cancer in EMERALD-3 Phase III Trial
April 03, 2026
WILMINGTON, Delaware, April 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

IMFINZI(R) (durvalumab) plus IMJUDO(R) (tremelimumab-actl) combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

IMFINZI plus IMJUDO combined with lenvatinib and transarterial c . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products